Rothfuss Cristin 4
4 · Sarepta Therapeutics, Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Rothfuss Cristin
EVP, General Counsel
Transactions
- Tax Payment
Common Stock
2025-03-03$103.77/sh−391$40,574→ 13,621 total
Footnotes (2)
- [F1]Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.
- [F2]Amount of Securities Beneficially Owned includes 195 shares purchased under the Company's registered Employee Stock Purchase Plan on February 28, 2025.